AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

In 2025, Turbine took the first steps in opening its powerful cell simulation platform to the wider drug development ...

Stakeholders across the life sciences ecosystem are invited to attend the 2025 Critical Path Institute® (C-Path) Global ...

Medpace beats Q2 2025 earnings, raises FY guidance, showcasing strong biotech demand. Click here to read an analysis of MEDP ...

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no ...

A potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival ...

ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc ...